These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 26253007)

  • 1. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.
    Klyuchnikov E; Bacher U; Woo Ahn K; Carreras J; Kröger NM; Hari PN; Ku GH; Ayala E; Chen AI; Chen YB; Cohen JB; Freytes CO; Gale RP; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Martino R; Mussetti A; Savani BN; Schouten HC; Usmani SZ; Wiernik PH; Wirk B; Smith SM; Sureda A; Hamadani M
    Bone Marrow Transplant; 2016 Jan; 51(1):58-66. PubMed ID: 26437062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
    Smith SM; Godfrey J; Ahn KW; DiGilio A; Ahmed S; Agrawal V; Bachanova V; Bacher U; Bashey A; Bolaños-Meade J; Cairo M; Chen A; Chhabra S; Copelan E; Dahi PB; Aljurf M; Farooq U; Ganguly S; Hertzberg M; Holmberg L; Inwards D; Kanate AS; Karmali R; Kenkre VP; Kharfan-Dabaja MA; Klein A; Lazarus HM; Mei M; Mussetti A; Nishihori T; Ramakrishnan Geethakumari P; Saad A; Savani BN; Schouten HC; Shah N; Urbano-Ispizua A; Vij R; Vose J; Sureda A; Hamadani M
    Cancer; 2018 Jun; 124(12):2541-2551. PubMed ID: 29645093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
    Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Laport GG; Montoto S; Maloney DG; Lazarus HM
    Biol Blood Marrow Transplant; 2013 May; 19(5):746-53. PubMed ID: 23380340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
    Epperla N; Ahn KW; Armand P; Jaglowski S; Ahmed S; Kenkre VP; Savani B; Jagasia M; Shah NN; Fenske TS; Sureda A; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):78-85. PubMed ID: 29032272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
    Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
    J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
    Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A
    Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
    Fenske TS; Zhang MJ; Carreras J; Ayala E; Burns LJ; Cashen A; Costa LJ; Freytes CO; Gale RP; Hamadani M; Holmberg LA; Inwards DJ; Lazarus HM; Maziarz RT; Munker R; Perales MA; Rizzieri DA; Schouten HC; Smith SM; Waller EK; Wirk BM; Laport GG; Maloney DG; Montoto S; Hari PN
    J Clin Oncol; 2014 Feb; 32(4):273-81. PubMed ID: 24344210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.
    Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Lazarus HM
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):625-31. PubMed ID: 23333532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.
    Wirk B; Fenske TS; Hamadani M; Zhang MJ; Hu ZH; Akpek G; Aljurf MD; Armand P; Ayala E; Bachanova V; Bolwell B; Cairo MS; Cashen A; Chen YB; Costa LJ; Farhan S; Freytes CO; Gajewski JL; Gibson J; Hale GA; Holmberg LA; Hsu JW; Inwards DJ; Kamble RT; Maharaj D; Maziarz RT; Munker R; Nath R; Reddy NM; Reeder CB; Rizzieri DA; Sauter CS; Savani BN; Schouten HC; Sureda A; Vose JM; Waller EK; Wiernik PH; Gale RP; Burns LJ; Saber W
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):951-9. PubMed ID: 24641828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
    Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
    Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
    Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
    J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?
    Hamadani M; Horowitz MM
    J Oncol Pract; 2017 Dec; 13(12):798-806. PubMed ID: 29232542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
    Hamadani M; Hari PN; Zhang Y; Carreras J; Akpek G; Aljurf MD; Ayala E; Bachanova V; Chen AI; Chen YB; Costa LJ; Fenske TS; Freytes CO; Ganguly S; Hertzberg MS; Holmberg LA; Inwards DJ; Kamble RT; Kanfer EJ; Lazarus HM; Marks DI; Nishihori T; Olsson R; Reddy NM; Rizzieri DA; Savani BN; Solh M; Vose JM; Wirk B; Maloney DG; Smith SM; Montoto S; Saber W; Alpdogan O; Cashen A; Dandoy C; Finke R; Gale R; Gibson J; Hsu JW; Janakiraman N; Laughlin MJ; Lill M; Cairo MS; Munker R; Rowlings PA; Schouten HC; Shea TC; Stiff PJ; Waller EK
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1729-36. PubMed ID: 25008330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
    Mussetti A; Devlin SM; Castro-Malaspina HR; Barker JN; Giralt SA; Zelenetz AD; Sauter CS; Perales MA
    Bone Marrow Transplant; 2015 Oct; 50(10):1293-1298. PubMed ID: 26146802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
    Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
    Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.